Orexo To Participate In Pareto Securities ́ 15Th Annual Healthcare Conference 2024
(MENAFN- PR Newswire)
UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ --
Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY ) , today announces
the company will participate in
Pareto Securities' 15th
Annual Healthcare Conference, that takes place on September 19, at Downtown Camper by Scandic, Brunkebergstorg 9, Stockholm, Sweden.
On the day, between 2:25-2:45 CET (room Event Small), Robert Rönn, SVP and Head of R&D,
will give a company presentation. Robert Rönn and Lena Wange, Investor Relations, will also be available for 1-1 meetings.
For more information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
+46 18 780 88 00
[email protected]
About
Orexo
Orexo is a Swedish pharmaceutical company with nearly 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
About AmorphOX®
Orexo's world-class drug delivery technology, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.
For more information about the company please visit . You can also follow Orexo on X, LinkedIn, and YouTube.
The information was submitted for publication at 9 am CET on September 3, 2024.
This information was brought to you by Cision
,c4032221
The following files are available for download:
| ,c3329843 |
4032221_0.png |
| ,c3329844 |
4032221_1.png |
MENAFN03092024003732001241ID1108629363
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.